ReviewJournal of the National Medical Association2004
The clinical spectrum of amiodarone-associated optic neuropathy.
Review in Journal of the National Medical Association, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Absence of bilateral vision loss from amiodarone: a randomized trial.American heart journal · 2007Trial
- Amiodarone-induced ocular and extra-ocular toxicity: a retrospective cohort study.Clinical and experimental medicine · 2025Observational
- Amiodarone-related keratopathy and optic neuropathy: case report and literature review.Frontiers in medicine · 2025Article
- Amiodarone Therapy: Updated Practical Insights.Journal of clinical medicine · 2024Review
- Artemisinin conferred cytoprotection to human retinal pigment epithelial cells exposed to amiodarone-induced oxidative insult by activating the CaMKK2/AMPK/Nrf2 pathway.Journal of translational medicine · 2024Article
- Article
- Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy.Biomolecules · 2022Review
- Adverse reactions of Amiodarone.Journal of geriatric cardiology : JGC · 2019Review
- Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?Neuro-ophthalmology (Aeolus Press) · 2018Article
- Amiodarone-Associated Optic Neuropathy: Clinical Review.Neuro-ophthalmology (Aeolus Press) · 2017Review
- Short-term treatment with oral amiodarone resulting in bilateral optic neuropathy and permanent blindness.BMJ case reports · 2017Article
- Metabolic, hereditary, traumatic, and neoplastic optic neuropathies.Continuum (Minneapolis, Minn.) · 2014Review
- Behaviour of disc oedema during and after amiodarone optic neuropathy: case report.Journal of clinical and diagnostic research : JCDR · 2014Article
- Amiodarone-associated optic neuropathy: a critical review.The American journal of medicine · 2012Review
- Unusual amiodarone toxicity in a child.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the clinical spectrum of amiodarone-associated optic neuropathy.
methodsObservational cases series and review.
resultsOf 55 cases, the median interval for onset of optic neuropathy was four months after initiating amiodarone; 88% occurred within 12 months. Seven (13%) patients were asymptomatic. Twenty-two (40%) patients presented with sudden visual loss, while 26 (47%) had insidious loss of vision. Visual acuity ranged from 20/15 to light perception; 10 (18%) patients had legal blindness with visual acuity of 20/200 or worse. Visual field loss was present in 91% of cases. Color vision loss was present in eight (40%) of 20 cases. Optic disc edema was present in 85% of cases, while eight (15%) patients had retrobulbar optic neuropathy, without evidence of disc edema. Optic disc edema resolved over a median time of three months. Five patients had raised intracranial pressure on lumbar puncture.
conclusionWe were able to classify amiodarone-associated optic neuropathy into five clinical categories with respect to temporal characteristics and optic nerve appearance: insidious-onset (43%), acute-onset (28%), retrobulbar (13%), increased intracranial pressure (8%), and delayed-progressive onset (8%). Most cases of optic neuropathy commenced within 12 months of initiating amiodarone, with the median onset being four months. Over 10% of patients will have no visual symptoms at the onset. Ophthalmologic examinations within the first 12 months--and particularly within four months of initiating amiodarone--should improve early detection of amiodarone-associated optic neuropathy.
Indexed as
Identifiers
15586652PMC2568612W10984423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.